(XBI) S&P Biotech - Overview
ETF Category: Health | Exchange: NYSE ARCA (USA) | Market Cap: 7.906m USD | Total Return: 66.6% in 12m
Avg Turnover: 1.08B
Warnings
No concerns identified
Tailwinds
No distinct edge detected
The SPDR S&P Biotech ETF (XBI) tracks the S&P Biotechnology Select Industry Index using a sampling strategy, typically investing at least 80% of its assets in the indexs component securities. This index captures the biotechnology segment of the broader S&P Total Market Index, providing targeted exposure to companies involved in medical research and drug development.
The biotechnology sector is characterized by high research and development (R&D) costs and long regulatory approval cycles through the FDA. Unlike traditional pharmaceutical companies, many biotech firms in this index operate on a pre-revenue basis, relying on venture capital or equity offerings to fund clinical trials before achieving commercial viability.
Investors can further evaluate the underlying fundamentals of these holdings by using the tools available on ValueRay.
- Interest rate cuts decrease capital costs for pre-revenue clinical stage companies
- FDA approval cycles and regulatory shifts dictate valuation of underlying small-cap holdings
- Pharmaceutical acquisition volume and premium levels drive sector-wide liquidity events
- Clinical trial success rates determine binary price movements for equal-weighted constituents
- Federal funding levels for healthcare research impact early-stage biotech pipeline development
As of May 26, 2026, the stock is trading at USD 131.66 with a total of 6,467,700 shares traded.
Over the past week, the price has changed by +0.74%,
over one month by -1.22%,
over three months by +1.94% and
over the past year by +66.64%.
S&P Biotech has no consensus analysts rating.